VitroScan develops predictive ex vivo 3D micro tumor testing from a centralized
lab in Leiden. In the fi rst place to improve patient outcomes through supporting better informed treatment decisions by identifi cation of the most effective drugs prior to treatment, and thus also facilitating cost-effective distribution of fi nite resources in healthcare.

In parallel, the company offers ex vivo tumor testing services in the context of clinical trials that enable pharmaceutical companies to de-risk clinical development and successfully deliver effective novel drugs to the market and cancer patients.

Product and service summary

VitroScan’s highly translational 3D ex vivo micro tumor platform aims to increase
the likelihood of success in drug development:

• Near clinical testing capturing the real-world patient population (run project
  within clinical trial in indication of interest)
• Reduce costs by effective selection of target indications
• Identify optimal (combination) therapies by testing drugs in parallel
• Proven predictive for true projections of clinical outcome
• Perform complementary assay to identify biomarkers

Contact

Willemijn Vader, CEO
solutions@vitroscan.nl
VitroScan, Leiden Bio Science Park, The Netherlands
https://vitroscan.nl/